We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter covers issues most likely to be raised by young women who have been diagnosed with breast cancer or those at high risk of the disease contemplating assisted fertility procedures. The type of adjuvant regimen selected for an individual woman is determined by menopause status, biological characteristics of the tumor and risk of relapse. Large meta-analyses of multiple trials with longterm follow-up have been used to assess the effects of systemic therapy on breast cancer outcomes. Achievement of amenorrhea appears to be associated with a reduction in relapse and improvement in survival in premenopausal women with estrogen receptor positive (ER+) tumors. There are three main barriers to implementing fertility preservation in women with breast cancer: cost; concern about treatment delays; and concern that increasing sex hormones as a result of controlled ovarian stimulation (COS) protocols will stimulate proliferation in ER+ tumors.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.